Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valganciclovir in CMV+ Major Depressive Disorder
NCT04724447Phase 2Completed
- Start
- Nov 2021
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in major depressive disorder (MDD) comparing Valganciclovir with Placebo (2 arms). Primary endpoint: White matter integrity of the inferior fronto-occipital fasciculus at 8 weeks. Started Nov 2021; status: completed.
02
Drugs
valganciclovir
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04724447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04724447.